Not an actual patient or HCP

Patient challenges
with dilation

Order Now

Dilation is a crucial but often disruptive approach to protecting eye health1‑4

Not an actual patient

Have your patients ever refused dilation or had concerns about how long their eyes will remain dilated after their exam?You're not alone.5,6

Potential patient challenges with dilation may include:

Dilation
duration3,4

Impaired eyesight
due to dilation3,4

Patient hesitancy or refusal may stem from concerns about how long their pupils may remain dilated post‑exam.3‑6

Dilation may disrupt your patient's day7,8

The effects of dilation may last longer than your patients expect.3,4

Dilating your patient's eyes can be inconvenient, but protecting their vision and eye health is important. Dilation may impact your patient's ability to read, use electronic devices, or even drive.3,4,7-9

Reading

Driving

Using electronic devices

Eye dilation may last anywhere from 6 to 24 hours, and during that time, your patients may experience issues with their eyes, such as sensitivity to light and blurred vision.3,4

Important Safety Information

Warnings and Precautions

  • Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
  • Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
  • Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Indication

RYZUMVI™ (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Click here for full Prescribing Information.

References: 1. Boyd K. Mendoza O. What are dilating eye drops? American Academy of Ophthalmology. Available at: https://www.aao.org/eye-health/drugs/dilating-eyedrops. Accessed February 8, 2024. 2. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation preferred practice pattern. American Academy of Ophthalmology. 2020;1-29. 3. Paremyd. Prescribing Information. Akorn, Inc. 2001. 4. Tropicamide. Prescribing Information. Alcon Laboratories, Inc. 2022. 5. Murphy J. How often do you dilate? Review of Optometry. Available at: https://www.reviewofoptometry.com/
article/how-often-do-you-dilate. Accessed February 8, 2024. 6. American Academy of Ophthalmology. 2 points to keep in mind when patients decline dilation. Available at: https://www.aoa.org/news/practice-management/billing-and-coding/2-points-to-keep-in-mind-when-patients-decline-dilation? Accessed February 8, 2024. 7. Goel S, Maharajan P, Chua C, Dong B, Butcher M, Bagga P. Driving ability after pupillary dilatation. Eye. 2003;17(6):735-738. 8. Siderov J, Bartlett JR, Madigan CJ. Pupillary dilation: the patient's perspective. Clin Exp Optom. 1996; 79(2): 62-66. 9. Adediji AK, Adio AO, Fiebai B. Effects of diagnostic mydriasis on distant and near vision. IOSR J Dent Med Sci. 2019;18(3):45-49.